Thymidylate synthase

2020 Market Spotlight: Basal Cell Carcinoma - ResearchAndMarkets.com

Retrieved on: 
Friday, April 17, 2020
Pharmaceutical, Health, Oncology, Branches of biology, RTT, Histopathology, Carcinoma, Biology, Basal-cell carcinoma, Hedgehog signaling pathway, Thymidylate synthase, PTCH2, Hedgehog pathway inhibitors

The "Market Spotlight: Basal Cell Carcinoma (2020)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Market Spotlight: Basal Cell Carcinoma (2020)" report has been added to ResearchAndMarkets.com's offering.
  • This Market Spotlight covers the basal cell carcinoma market, comprising key marketed and pipeline drugs, epidemiology, recent events and analyst opinion, clinical trials, upcoming events, probability of success, patent information, and licensing and acquisition deals.
  • The approved drugs in the basal cell carcinoma space target the immune system, thymidylate synthase, reactive oxygen species/free radicals, and Hedgehog signaling pathway.
  • Roche leads industry sponsors with the highest overall number of clinical trials for basal cell carcinoma, followed by Novartis.

Insights Into the 2019 Worldwide Pancreatic Cancer Market: 495,900 Incident Cases Expected by 2026 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 26, 2019
Pharmaceutical, Health, Oncology, Thymidylate synthase, Tubulin, Branches of biology, Oncology, Antineoplastic drugs, Organofluorides, Chemotherapy

The author estimates that in 2017, there were 453,200 incident cases of pancreatic cancer worldwide, and expects that number to increase to 495,900 incident cases by 2026.

Key Points: 
  • The author estimates that in 2017, there were 453,200 incident cases of pancreatic cancer worldwide, and expects that number to increase to 495,900 incident cases by 2026.
  • The approved drugs in the pancreatic cancer space target microtubules (tubulin), DNA, DNA synthesis, topoisomerase I, dihydropyrimidine dehydrogenase, thymidylate synthase, and epidermal growth factor receptor.
  • The majority of industry-sponsored drugs in active clinical development for pancreatic cancer are in Phase II.
  • Roche leads the industry sponsors with the highest number of clinical trials for pancreatic cancer, followed by Eli Lilly.

Global Mesothelioma Market Spotlight Report 2019: 10 Year Prevalence Forecast, Licensing and Acquisition Deals, & Drug-Specific Revenue Forecasts

Retrieved on: 
Wednesday, June 19, 2019
Enzymes, Cancer, RTT, Thymidylate synthase, Mesothelioma, Dihydrofolate reductase, Pemetrexed

DUBLIN, June 18, 2019 /PRNewswire/ -- The "Market Spotlight: Mesothelioma" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, June 18, 2019 /PRNewswire/ -- The "Market Spotlight: Mesothelioma" report has been added to ResearchAndMarkets.com's offering.
  • The approved drugs in the mesothelioma space target thymidylate synthase and dihydrofolate reductase.
  • There were seven licensing and asset acquisition deals involving mesothelioma drugs during 2014-18.
  • Eli Lilly has the highest number of completed clinical trials for mesothelioma, with 42 trials.